According to filings with the U.S. Securities and Exchange Commission, Omega Ophthalmics is raising up to $9,600,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Omega Ophthalmics
Omega Ophthalmics is a company focused on revolutionizing vision care through novel advancements, specifically targeting the outcomes of cataract surgery. The company has developed a proprietary lens called the Omega Gemini Refractive Capsule, which aims to significantly improve post-surgery vision, allowing over 90% of patients to be glasses free after the procedure. This innovation seeks to address the current limitation where approximately 50% of patients still require glasses after cataract surgery, a market that has seen little disruptive change in over sixty years. With the global intraocular lens market projected to reach $4.3 billion by 2017, Omega Ophthalmics positions its Gemini Refractive Capsule to become the new standard lens for cataract surgery, despite it currently being an investigational device not yet approved for use in the United States.

To learn more about Omega Ophthalmics, visit https://www.omegaophthalmics.com/
Omega Ophthalmics Linkedin Page: https://www.linkedin.com/search/results/companies/?keywords=Omega%20Ophthalmics

Contact:
Rick Ifland, Chief Executive Officer
859-227-4134
https://www.linkedin.com/in/rick-ifland-38383529/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.